Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Irinotecan in Esophageal Cancer
NCT00012363Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2001
- Primary completion
- Apr 2006
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in esophageal cancer, gastroesophageal junction cancer, sponsored by SWOG Cancer Research Network. Started Apr 2001; status: completed.
02
Drugs
gemcitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00012363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012363.